| Reply to CT Matava et al S Alexander, JA Kairalla, S Gupta, E Hibbitts, H Weisman, D Anghelescu, ... Journal of Clinical Oncology, JCO-24-01244, 2024 | | 2024 |
| Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group E Stieglitz, AG Lee, SP Angus, C Davis, DA Barkauskas, D Hall, ... Cancer Discovery, OF1-OF9, 2024 | 3 | 2024 |
| Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL): Post hoc analysis of adverse events of interest … E Aoki, LD Maese, M Loh, S Agarwal, V Chandrasekaran, Y Liang, ... Journal of Clinical Oncology 42 (16_suppl), 6521-6521, 2024 | | 2024 |
| Comparison of immunoglobulin high-throughput sequencing MRD in bone marrow and peripheral blood in pediatric B-ALL: A report from the Children's Oncology Group AALL1731. R Rau, S Gupta, JA Kairalla, C Wang, LW Lee, HM Simmons, KR Rabin, ... Journal of Clinical Oncology 42 (16_suppl), 10014-10014, 2024 | | 2024 |
| Germ line genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children CS Escherich, W Chen, Y Li, W Yang, R Nishii, Z Li, EA Raetz, M Devidas, ... Blood 143 (22), 2270-2283, 2024 | 1 | 2024 |
| MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231 RJ Hayashi, ML Hermiston, BL Wood, DT Teachey, M Devidas, Z Chen, ... Blood 143 (20), 2053-2058, 2024 | 1 | 2024 |
| Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study S Alexander, JA Kairalla, S Gupta, E Hibbitts, H Weisman, D Anghelescu, ... Journal of Clinical Oncology, JCO. 23.01989, 2024 | 3 | 2024 |
| Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report NJ DelRocco, ML Loh, MJ Borowitz, S Gupta, KR Rabin, ... Leukemia 38 (4), 720-728, 2024 | 1 | 2024 |
| Integrative longitudinal genomic analysis of therapy-resistant and metastatic pediatric cancers HJ Martell, AT Shah, AG Lee, SG Leung, SJ Cho, MP Ventura, A Golla, ... Cancer Research 84 (6_Supplement), 1759-1759, 2024 | | 2024 |
| Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group Trial AALL0232 LA Mattano Jr, M Devidas, ML Loh, EA Raetz, Z Chen, NJ Winick, ... Leukemia 38 (2), 258-265, 2024 | 3 | 2024 |
| Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group KR Rabin, M Devidas, Z Chen, L Ji, J Kairalla, JK Hitzler, JJ Yang, ... Journal of Clinical Oncology 42 (2), 218-227, 2024 | 5 | 2024 |
| Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study BL Wood, M Devidas, RJ Summers, Z Chen, B Asselin, KR Rabin, ... Blood 142 (24), 2069-2078, 2023 | 15 | 2023 |
| Hemophagocytic lymphohistiocytosis and clonally related T-cell malignancies in a pediatric patient LK Meyer, I Huang, BJ Huang, JH Chung, A Pawar, ML Hermiston, ... Pediatric blood & cancer 70 (12), e30677, 2023 | | 2023 |
| Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children's … SI Colace, M Devidas, ZB Chen, RJ Hayashi, BL Wood, N Esiashvili, ... Blood 142, 517, 2023 | 2 | 2023 |
| Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia SR Rheingold, L Ji, L Gore, X Xu, D Bhojwani, NN Shah, EA Raetz, ... Blood 142, 2876, 2023 | 1 | 2023 |
| Heritable Variation in Lymphocyte-Related Traits and Risk of Down Syndrome Acute Lymphoblastic Leukemia: A Mendelian Randomization Study Y Li, MA Richard, L Kachuri, Y Yu, CJR Hsu, TC Rosser, EJ Leslie, ... Blood 142, 4198, 2023 | | 2023 |
| The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia S Yoshimura, Z Li, Y Gocho, W Yang, KR Crews, SHR Lee, KG Roberts, ... Blood 142, 596, 2023 | | 2023 |
| Next-Generation Sequencing (NGS) for Residual Disease (MRD) Monitoring in T-Lymphoblastic Leukemia (T-ALL) N Roy, ZJ Mao, C Xu, DT Teachey, ZB Chen, M Devidas, X Chen, ... Blood 142, 2976, 2023 | | 2023 |
| Immunogenicity of Recombinant Erwinia asparaginase (JZP458) for Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) L Maese, ML Loh, MR Choi, Y Liang, E Aoki, S Roller, T Lin, S Agarwal, ... Blood 142, 5908, 2023 | | 2023 |
| CXCR3/CXCL10 Signaling Pathway Drives T-ALL into the CNS/Meningeal Microenvironment ND Sharma, W Ornatowski, M Nysus, S Paul, Q Jacquez, BL Myers, ... Blood 142, 37, 2023 | | 2023 |
